https://allsci.com/news/regulatory-setbacks-safety/kalydeco-eu-application-vertex-withdraws-for/ AllScien 2026-09-18T16:33:05.134614Z Vertex withdraws EU filings to expand Kaftrio/Kalydeco to younger children https://allsci.com/news/clinical-trials/teclistamab-label-expansion-chmp-backs-johnson/ AllScien 2026-09-18T16:15:58.277788Z Tecvayli expansion among September CHMP highlights https://allsci.com/news/clinical-trials/orum-aml-program-bms-ends-orums-extinguishing-usd/ AllScien 2026-09-18T15:29:28.685126Z BMS ends Orum’s AML program, extinguishing USD 80m in remaining milestone obligations https://allsci.com/news/approvals/sanfilippo-syndrome-treatment-ultragenyx-secures/ AllScien 2026-09-18T13:33:45.863682Z Ultragenyx secures FDA approval for first treatment of Sanfilippo syndrome type A https://allsci.com/news/research/ai-drug-discovery-stanfords-virtual-biotech-links/ AllScien 2026-09-18T13:04:57.480363Z Stanford Virtual Biotech links target expression patterns to higher drug success https://allsci.com/news/approvals/pediatric-spasticity-merz-therapeutics-expands/ AllScien 2026-09-18T11:45:18.155158Z Merz Therapeutics expands Xeomin’s EU/EEA label to pediatric lower limb spasticity in cerebral palsy https://allsci.com/news/clinical-trials/ava6103-phase-i-trial-avactas-achieves-clinical/ AllScien 2026-09-18T11:24:21.365967Z Avacta’s FAP-activated exatecan PDC shows early clinical proof of mechanism https://allsci.com/news/licensing-and-partnerships/wuxitecan-2-license-xdc-grants-ona-exclusive/ AllScien 2026-09-18T11:05:46.706749Z WuXi XDC grants Ona exclusive global license to WuXiTecan-2 for single ADC https://allsci.com/news/licensing-and-partnerships/dualitas-roche-deal-lands-usd-365m-upfront-in/ AllScien 2026-09-18T11:01:04.417522Z Dualitas lands USD 36.5m upfront in Roche bispecific discovery deal worth up to USD 1b https://allsci.com/news/research/prime-assembly-boston-childrens-hospital-and/ AllScien 2026-09-18T10:57:10.710555Z Boston Children’s-led team develops prime assembly for large DNA insertions https://allsci.com/news/pipe-financing/lisata-acquisition-pivots-from-oncology-to/ AllScien 2026-09-18T09:28:21.327876Z Lisata pivots from oncology to metabolic disease with Marea acquisition and USD 225m financing https://allsci.com/news/pipe-financing/aethlon-medical-merger-agrees-to-with-north/ AllScien 2026-09-17T17:23:30.834104Z North Immunology to go public via Aethlon reverse merger backed by USD 180m PIPE https://allsci.com/news/venture-financing/matisse-pharmaceuticals-secures-eur-14m-series-to/ AllScien 2026-09-17T15:50:29.605494Z Matisse secures EUR 14m Series A to advance isupartob sodium into Phase II sepsis trial https://allsci.com/news/licensing-and-partnerships/novo-nordisk-deal-orbis-secures-up-to-usd-14b-for/ AllScien 2026-09-17T15:41:51.824725Z Novo signs up for Orbis macrocycle platform in USD 1.4b deal https://allsci.com/news/clinical-trials/als-clinical-trial-acelot-begins-first-in-human/ AllScien 2026-09-17T14:44:33.881998Z Acelot takes TDP-43 ALS drug ACE-2223 into first-in-human trial https://allsci.com/news/approvals/kerendia-approval-fda-expands-bayers-to-type-1/ AllScien 2026-09-17T14:25:35.996784Z FDA expands Bayer’s Kerendia to type 1 diabetes-associated chronic kidney disease https://allsci.com/news/venture-financing/thyroid-eye-disease-sling-secures-usd-123m-to/ AllScien 2026-09-17T13:54:06.326894Z Sling secures USD 123m to advance oral TED drug linsitinib https://allsci.com/news/grants/male-contraceptive-weill-cornell-receives-207/ AllScien 2026-09-17T12:32:53.979312Z Weill Cornell wins USD 2.1m NIH grant to advance on-demand male contraceptive into Phase I https://allsci.com/news/clinical-trials/lunsumio-approval-roches-celestimo-win-supports/ AllScien 2026-09-17T11:02:56.600146Z Roche’s Lunsumio combination hits Phase III PFS goal in 2L+ follicular lymphoma https://allsci.com/news/licensing-and-partnerships/parkinsons-drug-sk-biopharmaceuticals-licenses/ AllScien 2026-09-17T10:41:15.603137Z SK Bio licenses Parkinson’s candidate 1ST-104 in USD 314.8m deal https://allsci.com/news/first-in-human-trials/ak158d1-clearance-akesos-receives-nmpa-phase-i/ AllScien 2026-09-17T10:19:38.996775Z Akeso’s EGFR/TROP2 bispecific ADC cleared for Phase I testing in China https://allsci.com/news/research/lung-cancer-immune-evasion-penn-preclinical-study/ AllScien 2026-09-17T09:37:48.506795Z UPenn study identifies NSD2–SETD2–EZH2 axis in KRAS lung cancer immunity https://allsci.com/news/licensing-and-partnerships/bispecific-adc-escugen-and-sovran-expand/ AllScien 2026-09-17T09:02:41.632736Z Escugen, Sovran pivot into co-development of pan-tumor bispecific MICA/B ADC https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-novo-expands-push-with/ AllScien 2026-09-17T08:49:59.498009Z Novo expands AI drug discovery push with Anthropic’s Claude Science collaboration https://allsci.com/news/venture-financing/circle-pharma-raises-usd-925m-to-advance-cid-165/ AllScien 2026-09-16T18:23:12.873332Z Circle Pharma raises USD 92.5m in Series E for cyclin D inhibitor https://allsci.com/news/research/human-cortical-organoids-stanford-researchers/ AllScien 2026-09-16T18:19:08.521694Z Stanford builds mice with human cortical tissue to model brain development https://allsci.com/news/clinical-trials/sky-0515-huntingtons-disease-skyhawks-posts/ AllScien 2026-09-16T17:59:25.873144Z Skyhawk’s SKY-0515 shows 1.59-point cUHDRS advantage at 15 months in Huntington’s disease https://allsci.com/news/pipe-financing/dry-eye-trial-cambium-bio-secures-aud-1085m-to/ AllScien 2026-09-16T17:07:29.459783Z Cambium Bio secures AUD 10.85m for Phase III of topical dry eye biologic https://allsci.com/news/licensing-and-partnerships/in-vivo-car-t-tempest-expands-strategy-with/ AllScien 2026-09-16T17:00:13.135436Z Tempest secures option on Senlang’s clinical-stage lentiviral in vivo CAR-T platform https://allsci.com/news/approvals/wakix-japan-approval-approves-viatris-for/ AllScien 2026-09-16T16:53:14.162174Z Japan approves Viatris’ Wakix for narcolepsy and OSAS-related daytime sleepiness